[1]
Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy .. Nat. Rev. Cancer, 2021, 21(1), 37-50..
[http://dx.doi.org/10.1038/s41568-020-00308-y] [PMID: 33128031]
[http://dx.doi.org/10.1038/s41568-020-00308-y] [PMID: 33128031]
[2]
Sartori A, Corno C, De Cesare M. .; Scanziani, E.; Minoli, L.; Battistini, L.; Zanardi, F.; Perego, P. Efficacy of a selective binder of
α V β 3 integrin linked to the tyrosine kinase inhibitor sunitinib in ovarian carcinoma preclinical models. Cancers, 2019, 11(4). pii:
E531..
[http://dx.doi.org/10.3390/cancers11040531] [PMID: 31013908 ]
[http://dx.doi.org/10.3390/cancers11040531] [PMID: 31013908 ]
[3]
Corno C, Perego P. KiSS1 in regulation of metastasis and response to antitumor drugs .. Drug Resist. Updat., 2019, 42, 12-21..
[http://dx.doi.org/10.1016/j.drup.2019.02.001 ] [PMID: 30776659]
[http://dx.doi.org/10.1016/j.drup.2019.02.001 ] [PMID: 30776659]
[4]
Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy .. Cancer Chemother. Pharmacol., 2016, 77(1), 5-18..
[http://dx.doi.org/10.1007/s00280-015-2901-x] [PMID: 26589793]
[http://dx.doi.org/10.1007/s00280-015-2901-x] [PMID: 26589793]
[5]
Gatti L, Sevko A, De Cesare M. .; Arrighetti, N.; Manenti, G.; Ciusani, E.; Verderio, P.; Ciniselli, C.M.; Cominetti, D.; Carenini, N.; Corna, E.; Zaffaroni, N.; Rodolfo, M.; Rivoltini, L.; Umansky, V.; Perego, P. Histone deacetylase inhibitor-temozolomide cotreatment
inhibits melanoma growth through suppression of chemokine (C-C motif) ligand 2-driven signals. Oncotarget, 2014, 5(12),
4516-4528..
[http://dx.doi.org/10.18632/oncotarget.2065 ] [PMID: 24980831]
[http://dx.doi.org/10.18632/oncotarget.2065 ] [PMID: 24980831]
[6]
D’Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M. Perego, P.; Sadeghi, B.; Hassan, M.; Larsson, R.; Linder, S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.2011, Nat Med 17(12): 1636-40.
[http://dx.doi.org/10.1038/nm.2536] [PMID: 22057347]
[http://dx.doi.org/10.1038/nm.2536] [PMID: 22057347]
[7]
Perego P, Giarola M, Righetti S. C.; Supino, R.; Caserini, C.; Delia, D.; Pierotti, M.A.; Miyashita, T.; Reed, J.C.; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. 1996 Cancer Res 56(3): 556-62.
[PMID: 8564971]
[PMID: 8564971]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
4
2